The present invention addresses the problem of providing a novel dry eye therapeutic agent which has an exceptional therapeutic effect on dry eye and with which it is possible to actualize a drug effect over an extended period of time in the lacrimal gland tissue after administration of the drug, from the standpoint of the administration burden imposed on the patient. This dry eye therapeutic agent, containing nandrolone or an ester thereof or methenolone or an ester thereof, exhibits a therapeutic effect on dry eye by increasing the amount of tear lipocalin (TL) in the tears. Administering this dry eye therapeutic agent containing nandrolone or an ester thereof or methenolone or an ester thereof to the eyelid skin makes it possible to actualize a drug effect over an extended period of time in the lacrimal gland tissue.本發明所欲解決之課題，係提供一種乾眼症之治療效果優異，且由患者的藥劑投予負擔之觀點而言，藥物被投予之後，於淚腺組織中可長期地發揮藥效之新穎的乾眼症治療藥。含有諾龍或其酯、美替諾龍或其酯等之乾眼症治療劑係藉由使淚液中的淚液脂質運載蛋白(Tear lipocalin，TL)量增加，而對於乾眼症具有治療效果，且藉由將含有諾龍或其酯、美替諾龍或其酯等之乾眼症治療劑投予於眼瞼皮膚，而於淚腺組織中可長期地發揮藥效。
